BOA™ Biomedical’s GARNET™ therapeutic product begins First in Human clinical trial
March 18, 2021
BOA Biomedical’s GARNET™ therapeutic product begins FIH clinical trial
Empowering the world with transformative technologies to fight against infectious disease
Covid-19 Response
BOA Biomedical maintains a Compassionate Use program for circumstances where a patient with a life-threatening illness, such as COVID-19
World Class Collaborations in
the fight against infectious disease
BOA, DOD and their research agency, DARPA, focus research on diagnosing and treating sepsis.
BOA’s extracorporeal blood filtration technology was developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University
Advanced innovation to defend against pandemics, biothreats and global infectious disease
Detect
Rapid
detection
Recognize active infection and assess infection severity and sepsis within minutes in any setting, including the home.
Diagnose
Rapid pathogen identification
Accurately identify infection-causing pathogens, within one hour, without the need for blood cultures.
Treat
Pathogen toxin removal
Filter the toxic by-products of pathogens directly from a patient’s blood using an extracorporeal therapeutic filter.
Compassionate Use
Addressing unmet
medical needs
BOA Biomedical maintains a Compassionate Use (also called Expanded Access) program for circumstances where a patient with a life-threatening illness, such as COVID-19, requires treatment and the treating physician believes that the GARNET technology may be of benefit.
Department of Defense
DIAGNOSING AND TREATING SEPSIS
BOA, DOD and their research agency, DARPA, focus research on diagnosing and treating sepsis. BOA licensed the technology from Harvard University in 2018 and was awarded emergency grants from the Department of Defense in 2020.
Wyss Institute
Partnerships
BOA Biomedical, a Miraki Innovation company has licensed technology from Harvard’s Wyss Institute to develop devices that can diagnose and treat infectious diseases.
Press
Defense Department Plans Study of COVID-19 Blood-Purification Treatment
February 11, 2021
The study, expected to begin later this year, will take place at Walter Reed National Military Medical Center and at nonmilitary hospitals.
BOA Biomedical seeks to address antibiotic resistance and sepsis
September 19, 2020
Harvard’s Wyss Institute and VC firm Miraki Innovation have created a joint venture BOA Biomedical, which is developing a device that could diagnose and treat
Mass. Biomedical Company Works on Rapid Coronavirus Test
March 26, 2020
A Cambridge biomedical is developing a rapid coronavirus test that it hopes to have ready in a few months.